Fly News Breaks for February 21, 2020
Feb 21, 2020 | 07:26 EDT
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on NuVasive (NUVA) and raised his price target on shares to $92 from $87, following the company's earnings report. The analyst noted that "Spinal Hardware growth of 7.9% was led by continued adoption of the X360 system for lateral single-position surgery," and added that growth in the company's U.S. Spine business accelerated from ~5% in the first half of the year to ~9% in second half of the year "driven by new product launches and solid overall execution." He raised his estimates for Spinal Hardware, and raised his overall FY20 EPS estimate by 5c, in-line with the company's guidance.
News For NUVA From the Last 2 Days
There are no results for your query NUVA